Trial Profile
A 52-week, open label, parallel group, multicentre, phase III, randomised controlled trial to compare the efficacy and safety of salbutamol metered dose inhaler taken as required for relief of symptoms, and budesonide/formoterol Turbuhaler taken as required for relief of symptoms, and regular budesonide Turbuhaler plus salbutamol metered dose inhaler taken as required for relief of symptoms, in adult patients with asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide; Salbutamol
- Indications Asthma
- Focus Therapeutic Use
- Acronyms Novel START
- 06 Aug 2021 Results of a pooled analysis predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide from following clinical studies: Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1 & 2 and DREAM using biomarker-stratified trial-level attack rates published in the Thorax
- 20 May 2020 Results (n=74) of a qualitative analysis exploring mild asthma patients assessing experiences of using one of two different preventer regimens presented at the 116th International Conference of the American Thoracic Society
- 23 May 2019 Results published in the New England Journal of Medicine